CGON Projected Dividend Yield

CG Oncology Inc ( NASDAQ : CGON )

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene, for patients with bladder cancer. Co. is at a clinical stage and does not project to generate significant revenues if and until the U.S. Food and Drug Administration (FDA) approves its primary asset, cretostimogene.

21 YEAR PERFORMANCE RESULTS